Eris Lifesciences posts Q4FY26 earnings call recording
Eris Lifesciences Limited announced that the recording of its earnings conference call for the quarter and financial year ended March 31, 2026, is now available. Held on May 20, 2026, the call discussed the audited consolidated and standalone financial results. Stakeholders can access the recording via the company's website.
*this image is generated using AI for illustrative purposes only.
Eris Lifesciences Limited has informed the stock exchanges that the recording of its earnings conference call is now available. The call was held on May 20, 2026, to discuss the audited consolidated and standalone financial results of the company for the quarter and financial year ended March 31, 2026.
The disclosure was made in accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided a direct link for stakeholders to access the audio recording of the proceedings.
Conference Call Details
The earnings call covered the financial performance of the company for the specified period. Investors and interested parties can review the management's commentary and analysis by visiting the official website.
| Event | Details |
|---|---|
| Subject | Audited consolidated and standalone financial results for Q4 and FY ended March 31, 2026 |
| Date of Call | May 20, 2026 |
| Availability | Available on company website |
Access Information
The recording can be accessed via the following link on the company's website: https://eris.co.in/financials/ . The specific file name for the recording is "Q4 FY26-Earnings Call Recording".
The communication was signed by Milind Talegaonkar, Company Secretary & Compliance Officer of eris lifesciences .
Historical Stock Returns for Eris Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.04% | -2.19% | -2.34% | -19.34% | -10.76% | +89.61% |
How did Eris Lifesciences' revenue and profit margins for FY26 compare to its peers in the Indian specialty pharma segment, and what does this signal for its competitive positioning in FY27?
What strategic initiatives or product launches did Eris Lifesciences' management outline for FY27 that could drive the next phase of growth?
Given Eris Lifesciences' recent acquisitions and portfolio expansion, how is the company planning to integrate these assets to improve consolidated earnings in the coming quarters?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
